MYGN vs NTRA
MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions. NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
Side-by-side fundamentals
| Metric | MYGN | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $5.54 | $405.92 | |
| Market cap | $530M | $58.5B | |
| Net margin FY2025, SEC XBRL | -44.4% | -9.0% | NTRA higher |
| Gross margin FY2025, SEC XBRL | +69.9% | n/a | |
| Operating margin FY2025, SEC XBRL | -47.0% | -13.4% | NTRA higher |
| ROE FY2025, SEC XBRL | -99.4% | -12.2% | NTRA higher |
| ROA FY2025, SEC XBRL | -51.8% | -8.7% | NTRA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.40 | 0.04 | NTRA lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -1.6% | +35.9% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +6.7% | +41.1% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.14 | 1.29 | |
| 1-year return as of 2026-10-20 close | -29.9% | +115.2% | NTRA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.